The unique combination of expertise in both Fish Physiology and Molecular Cell Biology makes ZF-screens distinctive in this expanding market
ZF-pharma has developed patented technology for the automated in vivo high-throughput screening of pharmaceutical drug candidates against diseases. This is achieved through novel robotic screens using model systems such as zebrafish. We seek industrial partners that are interested in obtaining a license for this technology or, alternatively, would prefer to outsource screening of TB drugs to ZF-pharma.
NewCatch BV has developed a tool for use in sustainable aquaculture. The tool will first be used for reproduction of the highly valued fish species eel, pikeperch and sole. We seek industrial/aquaculture partners interested in obtaining a license for ZF-implants in other fish species.
NewCatch BV carries out fish reproductive research, for instance European eel (Anguilla anguilla), exploring maturation and reproduction. ZF-screens has its own research facilities to study reproductive biology in several fish species.
ZF-Genomics offers multiple Illumina services, including mRNAseq and microRNA analysis and de novo and reference genome assemblies.
ZF-Genomics is a department of ZF-Screens BV, which uses Next generation sequencing technology to support the core business activities of our daughter companies ZF-Pharma BV and NewCatch BV. In addition, we perform Next generation sequencing tasks for (inter)national research project partners and for external customers.
ZF Screens company J.H. Oortweg 19, 2333 CH Leiden The Netherlands Phone + 31 (0)71 332 22 70